川崎病におけるマルチオミクスアプローチ:病因論と診断・治療に向けた新たな方向性への洞察
Jong Gyun Ahn1,2,3, Insoo Kang3
1Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea.
Abstract:
Kawasaki disease (KD) is an acute febrile vasculitis and the leading cause of acquired heart disease in children. Despite decades of research, the etiology remains unknown and key mechanisms linking systemic inflammation to coronary artery lesions are incompletely defined. High-throughput technologies-including genomics, transcriptomics, proteomics, metabolomics, epigenomics, and immunomics-have enabled systems-level profiling of KD and highlighted reproducible inflammatory and vascular pathways. Multiomics integration increasingly supports convergent mechanistic axes, particularly interleukin (IL-1/IL-6-neutrophil programs, Fcγ-receptor signaling related to intravenous immunoglobulin (IVIG) pharmacodynamics, Ca²+/nuclear factor of activated T cells-dependent T-cell activation, and endothelial/extracellular matrix remodeling associated with coronary outcomes. While these findings provide a robust framework for biomarker discovery and therapeutic hypothesis generation, most signatures remain investigational and require prospective validation, standardized sampling (pre-/post-IVIG), and clinically scalable assays before routine implementation. This review summarizes current multiomics applications in KD, prioritizes the most consistently supported pathways, and outlines a pragmatic roadmap toward clinically useful risk stratification, disease monitoring, and outcome prediction.
さらに関連する動画
08:56Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
関連する概念動画
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pharmacogenomics: Identification of New Drug Targets
Rheumatic Heart Disease III: Medical Management
The JAK-STAT Signaling Pathway
Genomics
Rheumatic Heart Disease I: Introduction
